Source link : https://www.newshealth.biz/health-news/nemolizumab-effective-in-atopic-dermatitis/
TOPLINE: Nemolizumab, an interleukin 31 receptor antagonist, was well tolerated and significantly improved inflammation and pruritus in patients with moderate to severe atopic dermatitis (AD). METHODOLOGY: The researchers conducted two 48-week randomized, double-blind, placebo-controlled phase 3 trials, ARCADIA 1 (n = 941; 47% women) and ARCADIA 2 (n = 787; 52% women), involving patients ages […]
Author : News Health
Publish date : 2024-08-06 05:06:06
Copyright for syndicated content belongs to the linked Source.
Categories